FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use
Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:PAN3-FLT3

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: PAN3-FLT3
FusionPDB ID: 62518
FusionGDB2.0 ID: 62518
HgeneTgene
Gene symbol

PAN3

FLT3

Gene ID

255967

2322

Gene namepoly(A) specific ribonuclease subunit PAN3fms related receptor tyrosine kinase 3
Synonyms-CD135|FLK-2|FLK2|STK1
Cytomap

13q12.2

13q12.2

Type of geneprotein-codingprotein-coding
DescriptionPAN2-PAN3 deadenylation complex subunit PAN3PAB-dependent poly(A)-specific ribonuclease subunit 3PAB-dependent poly(A)-specific ribonuclease subunit PAN3PAB1P-dependent poly(A)-nucleasePAB1P-dependent poly(A)-specific ribonucleasePABP-dependent poly(receptor-type tyrosine-protein kinase FLT3CD135 antigenFL cytokine receptorfetal liver kinase 2fms related tyrosine kinase 3fms-like tyrosine kinase 3growth factor receptor tyrosine kinase type IIIstem cell tyrosine kinase 1
Modification date2020032020200329
UniProtAcc.

P49771

Main function of 5'-partner protein: FUNCTION: Stimulates the proliferation of early hematopoietic cells by activating FLT3. Synergizes well with a number of other colony stimulating factors and interleukins.
Ensembl transtripts involved in fusion geneENST idsENST00000380958, ENST00000399613, 
ENST00000282391, ENST00000483842, 
ENST00000469894, ENST00000241453, 
ENST00000380982, ENST00000537084, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score19 X 9 X 12=20528 X 9 X 5=360
# samples 209
** MAII scorelog2(20/2052*10)=-3.35895882583233
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0		log2(9/360*10)=-2
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: PAN3 [Title/Abstract] AND FLT3 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: PAN3 [Title/Abstract] AND FLT3 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)PAN3(28752072)-FLT3(28644749), # samples:3
Anticipated loss of major functional domain due to fusion event.PAN3-FLT3 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
PAN3-FLT3 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
PAN3-FLT3 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
PAN3-FLT3 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
PAN3-FLT3 seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF.
PAN3-FLT3 seems lost the major protein functional domain in Hgene partner, which is a kinase due to the frame-shifted ORF.
PAN3-FLT3 seems lost the major protein functional domain in Tgene partner, which is a CGC due to the frame-shifted ORF.
PAN3-FLT3 seems lost the major protein functional domain in Tgene partner, which is a IUPHAR drug target due to the frame-shifted ORF.
PAN3-FLT3 seems lost the major protein functional domain in Tgene partner, which is a kinase due to the frame-shifted ORF.
PAN3-FLT3 seems lost the major protein functional domain in Tgene partner, which is a tumor suppressor due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
TgeneFLT3

GO:0030097

hemopoiesis

7507245



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr13:28752072/chr13:28644749)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across PAN3 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across FLT3 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)		BP loci
(transcript)		Predicted start
(transcript)		Predicted stop
(transcript)		Seq length
(amino acids)
ENST00000380958PAN3chr1328794515+ENST00000241453FLT3chr1328644749-4869115215240901312
ENST00000380958PAN3chr1328794515+ENST00000380982FLT3chr1328644749-4875115215240991315
ENST00000380958PAN3chr1328794515+ENST00000537084FLT3chr1328644749-4227115215239671271
ENST00000399613PAN3chr1328794515+ENST00000241453FLT3chr1328644749-41804634834011117
ENST00000399613PAN3chr1328794515+ENST00000380982FLT3chr1328644749-41864634834101120
ENST00000399613PAN3chr1328794515+ENST00000537084FLT3chr1328644749-35384634832781076

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000380958ENST00000241453PAN3chr1328794515+FLT3chr1328644749-0.0003162760.99968374
ENST00000380958ENST00000380982PAN3chr1328794515+FLT3chr1328644749-0.0002043120.99979573
ENST00000380958ENST00000537084PAN3chr1328794515+FLT3chr1328644749-0.000261090.9997389
ENST00000399613ENST00000241453PAN3chr1328794515+FLT3chr1328644749-0.0002494410.99975055
ENST00000399613ENST00000380982PAN3chr1328794515+FLT3chr1328644749-0.0001580080.9998419
ENST00000399613ENST00000537084PAN3chr1328794515+FLT3chr1328644749-0.0002121160.99978787

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for PAN3-FLT3

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
PAN3chr1328794515FLT3chr13286447491152333PSMGSPATAGLAPVVFSAMIFGTITN
PAN3chr1328794515FLT3chr1328644749463138PSMGSPATAGLAPVVFSAMIFGTITN

Top

Potential FusionNeoAntigen Information of PAN3-FLT3 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
PAN3-FLT3_28794515_28644749.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
PAN3-FLT3chr1328794515chr13286447491152HLA-B51:01TAGLAPVV0.99810.9711715
PAN3-FLT3chr1328794515chr13286447491152HLA-B35:05APVVFSAM0.94140.58691119
PAN3-FLT3chr1328794515chr13286447491152HLA-A02:22GLAPVVFSA0.99840.5333918
PAN3-FLT3chr1328794515chr13286447491152HLA-A02:27GLAPVVFSA0.99810.6406918
PAN3-FLT3chr1328794515chr13286447491152HLA-A02:11GLAPVVFSA0.99790.5723918
PAN3-FLT3chr1328794515chr13286447491152HLA-A02:13GLAPVVFSA0.99790.7649918
PAN3-FLT3chr1328794515chr13286447491152HLA-A02:16GLAPVVFSA0.99780.5973918
PAN3-FLT3chr1328794515chr13286447491152HLA-A02:60GLAPVVFSA0.99770.5686918
PAN3-FLT3chr1328794515chr13286447491152HLA-A02:67GLAPVVFSA0.99760.5582918
PAN3-FLT3chr1328794515chr13286447491152HLA-A02:30GLAPVVFSA0.99760.5582918
PAN3-FLT3chr1328794515chr13286447491152HLA-A02:24GLAPVVFSA0.99760.5582918
PAN3-FLT3chr1328794515chr13286447491152HLA-A02:38GLAPVVFSA0.99720.7248918
PAN3-FLT3chr1328794515chr13286447491152HLA-A02:21GLAPVVFSA0.9970.6561918
PAN3-FLT3chr1328794515chr13286447491152HLA-A02:04GLAPVVFSA0.99040.6479918
PAN3-FLT3chr1328794515chr13286447491152HLA-B35:01TAGLAPVVF0.9850.9691716
PAN3-FLT3chr1328794515chr13286447491152HLA-A02:35GLAPVVFSA0.98490.5853918
PAN3-FLT3chr1328794515chr13286447491152HLA-A02:17GLAPVVFSA0.9810.6331918
PAN3-FLT3chr1328794515chr13286447491152HLA-B35:05TAGLAPVVF0.97660.9011716
PAN3-FLT3chr1328794515chr13286447491152HLA-A02:29GLAPVVFSA0.96840.5597918
PAN3-FLT3chr1328794515chr13286447491152HLA-B53:01TAGLAPVVF0.95240.8183716
PAN3-FLT3chr1328794515chr13286447491152HLA-A02:20GLAPVVFSA0.94970.5621918
PAN3-FLT3chr1328794515chr13286447491152HLA-A02:21ATAGLAPVV0.93890.8651615
PAN3-FLT3chr1328794515chr13286447491152HLA-B15:17ATAGLAPVVF0.99790.9898616
PAN3-FLT3chr1328794515chr13286447491152HLA-B15:16ATAGLAPVVF0.99720.9837616
PAN3-FLT3chr1328794515chr13286447491152HLA-B57:03ATAGLAPVVF0.9970.9974616
PAN3-FLT3chr1328794515chr13286447491152HLA-B07:05SPATAGLAPV0.99490.6291414
PAN3-FLT3chr1328794515chr13286447491152HLA-B07:02SPATAGLAPV0.99440.6555414
PAN3-FLT3chr1328794515chr13286447491152HLA-B56:01SPATAGLAPV0.94230.7336414
PAN3-FLT3chr1328794515chr13286447491152HLA-A02:22AGLAPVVFSA0.9110.5152818
PAN3-FLT3chr1328794515chr13286447491152HLA-A02:16AGLAPVVFSA0.89170.5089818
PAN3-FLT3chr1328794515chr13286447491152HLA-B82:01SPATAGLAPV0.65610.7834414
PAN3-FLT3chr1328794515chr13286447491152HLA-B07:05SPATAGLAPVV0.99720.7019415
PAN3-FLT3chr1328794515chr13286447491152HLA-B07:02SPATAGLAPVV0.99670.752415
PAN3-FLT3chr1328794515chr13286447491152HLA-B07:12APVVFSAM0.98840.53931119
PAN3-FLT3chr1328794515chr13286447491152HLA-B39:10APVVFSAM0.83830.94841119
PAN3-FLT3chr1328794515chr13286447491152HLA-C15:06ATAGLAPVV0.99910.974615
PAN3-FLT3chr1328794515chr13286447491152HLA-C03:08LAPVVFSAM0.99790.91811019
PAN3-FLT3chr1328794515chr13286447491152HLA-A02:07GLAPVVFSA0.99760.6187918
PAN3-FLT3chr1328794515chr13286447491152HLA-A02:01GLAPVVFSA0.99760.5582918
PAN3-FLT3chr1328794515chr13286447491152HLA-C03:19LAPVVFSAM0.99750.99021019
PAN3-FLT3chr1328794515chr13286447491152HLA-C03:07LAPVVFSAM0.99480.98951019
PAN3-FLT3chr1328794515chr13286447491152HLA-C12:12LAPVVFSAM0.99410.95281019
PAN3-FLT3chr1328794515chr13286447491152HLA-A02:05ATAGLAPVV0.97390.8059615
PAN3-FLT3chr1328794515chr13286447491152HLA-C01:30LAPVVFSAM0.9140.96821019
PAN3-FLT3chr1328794515chr13286447491152HLA-C02:06ATAGLAPVV0.71660.992615
PAN3-FLT3chr1328794515chr13286447491152HLA-C03:14TAGLAPVVF0.6940.9935716
PAN3-FLT3chr1328794515chr13286447491152HLA-C01:17LAPVVFSAM0.65640.96891019
PAN3-FLT3chr1328794515chr13286447491152HLA-B07:12SPATAGLAPV0.98880.707414
PAN3-FLT3chr1328794515chr13286447491152HLA-B07:04SPATAGLAPV0.96320.6216414
PAN3-FLT3chr1328794515chr13286447491152HLA-B56:04SPATAGLAPV0.89350.7224414
PAN3-FLT3chr1328794515chr13286447491152HLA-B07:12SPATAGLAPVV0.99280.7804415
PAN3-FLT3chr1328794515chr13286447491152HLA-B56:04SPATAGLAPVV0.8860.7061415
PAN3-FLT3chr1328794515chr13286447491152HLA-B51:13TAGLAPVV0.99820.8752715
PAN3-FLT3chr1328794515chr13286447491152HLA-B35:17APVVFSAM0.93580.76231119
PAN3-FLT3chr1328794515chr13286447491152HLA-B35:30APVVFSAM0.93580.76231119
PAN3-FLT3chr1328794515chr13286447491152HLA-B67:01APVVFSAM0.83270.84521119
PAN3-FLT3chr1328794515chr13286447491152HLA-C15:02ATAGLAPVV0.99950.9748615
PAN3-FLT3chr1328794515chr13286447491152HLA-C15:05ATAGLAPVV0.99930.9821615
PAN3-FLT3chr1328794515chr13286447491152HLA-C03:04LAPVVFSAM0.99870.99271019
PAN3-FLT3chr1328794515chr13286447491152HLA-C03:03LAPVVFSAM0.99870.99271019
PAN3-FLT3chr1328794515chr13286447491152HLA-A02:03GLAPVVFSA0.99860.6977918
PAN3-FLT3chr1328794515chr13286447491152HLA-C03:05LAPVVFSAM0.99720.90551019
PAN3-FLT3chr1328794515chr13286447491152HLA-C03:02LAPVVFSAM0.99710.98211019
PAN3-FLT3chr1328794515chr13286447491152HLA-A02:06GLAPVVFSA0.9970.6561918
PAN3-FLT3chr1328794515chr13286447491152HLA-A02:14GLAPVVFSA0.99690.5876918
PAN3-FLT3chr1328794515chr13286447491152HLA-C03:17LAPVVFSAM0.99650.97781019
PAN3-FLT3chr1328794515chr13286447491152HLA-C03:02TAGLAPVVF0.99580.9917716
PAN3-FLT3chr1328794515chr13286447491152HLA-C12:03LAPVVFSAM0.99440.98941019
PAN3-FLT3chr1328794515chr13286447491152HLA-C16:04LAPVVFSAM0.98990.98781019
PAN3-FLT3chr1328794515chr13286447491152HLA-A68:02ATAGLAPVV0.98980.8253615
PAN3-FLT3chr1328794515chr13286447491152HLA-B35:11TAGLAPVVF0.98740.9835716
PAN3-FLT3chr1328794515chr13286447491152HLA-B35:23TAGLAPVVF0.9850.9751716
PAN3-FLT3chr1328794515chr13286447491152HLA-B35:77TAGLAPVVF0.9850.9691716
PAN3-FLT3chr1328794515chr13286447491152HLA-A69:01ATAGLAPVV0.97750.9012615
PAN3-FLT3chr1328794515chr13286447491152HLA-B35:30TAGLAPVVF0.97660.9487716
PAN3-FLT3chr1328794515chr13286447491152HLA-B35:17TAGLAPVVF0.97660.9487716
PAN3-FLT3chr1328794515chr13286447491152HLA-B35:13TAGLAPVVF0.95580.9767716
PAN3-FLT3chr1328794515chr13286447491152HLA-B35:24TAGLAPVVF0.95220.9683716
PAN3-FLT3chr1328794515chr13286447491152HLA-A02:06ATAGLAPVV0.93890.8651615
PAN3-FLT3chr1328794515chr13286447491152HLA-C03:06LAPVVFSAM0.93130.99361019
PAN3-FLT3chr1328794515chr13286447491152HLA-B53:02TAGLAPVVF0.90610.8087716
PAN3-FLT3chr1328794515chr13286447491152HLA-B35:43TAGLAPVVF0.73820.976716
PAN3-FLT3chr1328794515chr13286447491152HLA-B51:06TAGLAPVVF0.71290.8954716
PAN3-FLT3chr1328794515chr13286447491152HLA-C01:02LAPVVFSAM0.56660.96881019
PAN3-FLT3chr1328794515chr13286447491152HLA-C16:01TAGLAPVVF0.53020.9936716
PAN3-FLT3chr1328794515chr13286447491152HLA-C01:03LAPVVFSAM0.37780.96541019
PAN3-FLT3chr1328794515chr13286447491152HLA-B57:04ATAGLAPVVF0.99970.9503616
PAN3-FLT3chr1328794515chr13286447491152HLA-B57:02ATAGLAPVVF0.99910.9851616
PAN3-FLT3chr1328794515chr13286447491152HLA-B07:22SPATAGLAPV0.99440.6555414
PAN3-FLT3chr1328794515chr13286447491152HLA-B55:02SPATAGLAPV0.95130.7286414
PAN3-FLT3chr1328794515chr13286447491152HLA-B55:04SPATAGLAPV0.93550.6277414
PAN3-FLT3chr1328794515chr13286447491152HLA-B56:02SPATAGLAPV0.89350.7224414
PAN3-FLT3chr1328794515chr13286447491152HLA-B07:26SPATAGLAPV0.86230.5052414
PAN3-FLT3chr1328794515chr13286447491152HLA-B67:01SPATAGLAPV0.79150.9564414
PAN3-FLT3chr1328794515chr13286447491152HLA-B56:05SPATAGLAPV0.75140.6999414
PAN3-FLT3chr1328794515chr13286447491152HLA-B82:02SPATAGLAPV0.65610.7834414
PAN3-FLT3chr1328794515chr13286447491152HLA-B07:22SPATAGLAPVV0.99670.752415
PAN3-FLT3chr1328794515chr13286447491152HLA-B56:02SPATAGLAPVV0.8860.7061415
PAN3-FLT3chr1328794515chr13286447491152HLA-B67:01SPATAGLAPVV0.78650.9241415

Top

Potential FusionNeoAntigen Information of PAN3-FLT3 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)

Top

Fusion breakpoint peptide structures of PAN3-FLT3

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
641ATAGLAPVVFSAMIPAN3FLT3chr1328794515chr13286447491152

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of PAN3-FLT3

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN641ATAGLAPVVFSAMI-7.9962-8.1096
HLA-B14:023BVN641ATAGLAPVVFSAMI-5.70842-6.74372
HLA-B52:013W39641ATAGLAPVVFSAMI-6.83737-6.95077
HLA-B52:013W39641ATAGLAPVVFSAMI-4.4836-5.5189
HLA-A11:014UQ2641ATAGLAPVVFSAMI-10.0067-10.1201
HLA-A11:014UQ2641ATAGLAPVVFSAMI-9.03915-10.0745
HLA-A24:025HGA641ATAGLAPVVFSAMI-6.56204-6.67544
HLA-A24:025HGA641ATAGLAPVVFSAMI-5.42271-6.45801
HLA-B44:053DX8641ATAGLAPVVFSAMI-7.85648-8.89178
HLA-B44:053DX8641ATAGLAPVVFSAMI-5.3978-5.5112
HLA-A02:016TDR641ATAGLAPVVFSAMI-3.37154-4.40684

Top

Vaccine Design for the FusionNeoAntigens of PAN3-FLT3

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
PAN3-FLT3chr1328794515chr13286447491019LAPVVFSAMTAGCGCCAGTTGTTTTTTCTGCAATGA
PAN3-FLT3chr1328794515chr13286447491119APVVFSAMCGCCAGTTGTTTTTTCTGCAATGA
PAN3-FLT3chr1328794515chr1328644749414SPATAGLAPVGCCCTGCTACTGCTGGATTAGCGCCAGTTG
PAN3-FLT3chr1328794515chr1328644749415SPATAGLAPVVGCCCTGCTACTGCTGGATTAGCGCCAGTTGTTT
PAN3-FLT3chr1328794515chr1328644749615ATAGLAPVVCTACTGCTGGATTAGCGCCAGTTGTTT
PAN3-FLT3chr1328794515chr1328644749616ATAGLAPVVFCTACTGCTGGATTAGCGCCAGTTGTTTTTT
PAN3-FLT3chr1328794515chr1328644749715TAGLAPVVCTGCTGGATTAGCGCCAGTTGTTT
PAN3-FLT3chr1328794515chr1328644749716TAGLAPVVFCTGCTGGATTAGCGCCAGTTGTTTTTT
PAN3-FLT3chr1328794515chr1328644749818AGLAPVVFSACTGGATTAGCGCCAGTTGTTTTTTCTGCAA
PAN3-FLT3chr1328794515chr1328644749918GLAPVVFSAGATTAGCGCCAGTTGTTTTTTCTGCAA

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence

Top

Information of the samples that have these potential fusion neoantigens of PAN3-FLT3

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
LAMLPAN3-FLT3chr1328794515ENST00000380958chr1328644749ENST00000241453TCGA-AB-2853-03A

Top

Potential target of CAR-T therapy development for PAN3-FLT3

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
TgeneFLT3chr13:28713224chr13:28644749ENST00000241453024544_5630994.0TransmembraneHelical
TgeneFLT3chr13:28713224chr13:28644749ENST00000537084023544_5630953.0TransmembraneHelical
TgeneFLT3chr13:28794515chr13:28644749ENST00000241453024544_5630994.0TransmembraneHelical
TgeneFLT3chr13:28794515chr13:28644749ENST00000537084023544_5630953.0TransmembraneHelical

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to PAN3-FLT3

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to PAN3-FLT3

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource